Evaluation of rMETase-Loaded Stealth PLGA/Liposomes Modified with Anti-CAGE scFV for Treatment of Gastric Carcinoma
Stealth PLGA/Liposome nanoparticles (NPs) modified with tumor-targeting single-chain antibody fragment (scFV-P/L) for systemic delivery of recombinant methioninase (rMETase) for gastric cancer were prepared. The morphologies and therapeutic effects of rMETase-loaded scFV-P/L (scFV-rMETase-P/L) in vitro were analyzed. Functional scFV-P/L NPs composed of PLGA, DOPC and DSPE-PEG display low cell cytoxicity in SGC-7901 cells, and has more cell uptake ability than P/L NPs. scFV-rMETase-P/L was more effective in inhibiting tumor growth in the subcutaneous gastric carcinoma tumor model than free rMETase in solution (p < 0.05) and rMETase-loaded P/L (rMETase-P/L) (p < 0.05). Our findings collectively support the utility of scFV-targeted P/L NPs as a potentially effective drug delivery system.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: July 1, 2015
More about this publication?
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites